
<document id="DBMI.pac91" origId="pac91">
	<sentence id="DBMI.pac91.s0" origId="s0" text="12 CLINICAL PHARMACOLOGY\n\n12.1 Mechanism of Action\n\nThe precise mechanism by which atomoxetine produces its therapeutic effects in Attention-Deficit/Hyperactivity Disorder (ADHD) is unknown, but is thought to be related to selective inhibition of the pre-synaptic norepinephrine transporter, as determined in ex vivo uptake and neurotransmitter depletion studies."/>
	<sentence id="DBMI.pac91.s1" origId="s1" text="12.2 Pharmacodynamics\n\nAn exposure-response analysis encompassing doses of atomoxetine (0.5, 1.2 or 1.8 mg/kg/day) or placebo demonstrated atomoxetine exposure correlates with efficacy as measured by the Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator administered and scored."/>
	<sentence id="DBMI.pac91.s2" origId="s2" text="The exposure-efficacy relationship was similar to that observed between dose and efficacy with median exposures at the two highest doses resulting in near maximal changes from baseline [see Clinical Studies  (14.2)]."/>
	<sentence id="DBMI.pac91.s3" origId="s3" text="12.3 Pharmacokinetics\n\nAtomoxetine is well-absorbed after oral administration and is minimally affected by food."/>
	<sentence id="DBMI.pac91.s4" origId="s4" text="It is eliminated primarily by oxidative metabolism through the cytochrome P450 2D6 (CYP2D6) enzymatic pathway and subsequent glucuronidation."/>
	<sentence id="DBMI.pac91.s5" origId="s5" text="Atomoxetine has a half-life of about 5 hours."/>
	<sentence id="DBMI.pac91.s6" origId="s6" text="A fraction of the population (about 7% of Caucasians and 2% of African Americans) are poor metabolizers (PMs) of CYP2D6 metabolized drugs."/>
	<sentence id="DBMI.pac91.s7" origId="s7" text="These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (EMs)]."/>
	<sentence id="DBMI.pac91.s8" origId="s8" text="Drugs that inhibit CYP2D6, such as fluoxetine, paroxetine, and quinidine, cause similar increases in exposure.">
		<entity charOffset="1654-1665" id="DBMI.pac91.s8.e0" origId="s8.e0" text="fluoxetine " type="Active ingredient"/>
		<entity charOffset="1533-1545" id="DBMI.pac91.s8.e1" origId="s8.e1" text="atomoxetine " type="Active ingredient"/>
		<entity charOffset="1666-1677" id="DBMI.pac91.s8.e2" origId="s8.e2" text="paroxetine " type="Active ingredient"/>
		<entity charOffset="1682-1692" id="DBMI.pac91.s8.e3" origId="s8.e3" text="quinidine " type="Active ingredient"/>
		<pair e1="DBMI.pac91.s8.e0" e2="DBMI.pac91.s8.e1" id="DBMI.pac91.s8.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="atomoxetine " precipitant="fluoxetine "/>
		<pair e1="DBMI.pac91.s8.e0" e2="DBMI.pac91.s8.e2" id="DBMI.pac91.s8.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.s8.e0" e2="DBMI.pac91.s8.e3" id="DBMI.pac91.s8.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.s8.e1" e2="DBMI.pac91.s8.e0" id="DBMI.pac91.s8.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.s8.e1" e2="DBMI.pac91.s8.e2" id="DBMI.pac91.s8.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.s8.e1" e2="DBMI.pac91.s8.e3" id="DBMI.pac91.s8.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.s8.e2" e2="DBMI.pac91.s8.e0" id="DBMI.pac91.s8.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.s8.e2" e2="DBMI.pac91.s8.e1" id="DBMI.pac91.s8.p7" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="atomoxetine " precipitant="paroxetine "/>
		<pair e1="DBMI.pac91.s8.e2" e2="DBMI.pac91.s8.e3" id="DBMI.pac91.s8.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.s8.e3" e2="DBMI.pac91.s8.e0" id="DBMI.pac91.s8.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.s8.e3" e2="DBMI.pac91.s8.e1" id="DBMI.pac91.s8.p10" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="atomoxetine " precipitant="quinidine "/>
		<pair e1="DBMI.pac91.s8.e3" e2="DBMI.pac91.s8.e2" id="DBMI.pac91.s8.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac91.s9" origId="s9" text="The pharmacokinetics of atomoxetine have been evaluated in more than 400 children and adolescents in selected clinical trials, primarily using population pharmacokinetic studies."/>
	<sentence id="DBMI.pac91.s10" origId="s10" text="Single-dose and steady-state individual pharmacokinetic data were also obtained in children, adolescents, and adults."/>
	<sentence id="DBMI.pac91.s11" origId="s11" text="When doses were normalized to a mg/kg basis, similar half-life, Cmax, and AUC values were observed in children, adolescents, and adults."/>
	<sentence id="DBMI.pac91.s12" origId="s12" text="Clearance and volume of distribution after adjustment for body weight were also similar."/>
	<sentence id="DBMI.pac91.s13" origId="s13" text="Absorption and distribution Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in EMs and 94% in PMs."/>
	<sentence id="DBMI.pac91.s14" origId="s14" text="Maximal plasma concentrations (Cmax) are reached approximately 1 to 2 hours after dosing."/>
	<sentence id="DBMI.pac91.s15" origId="s15" text="Atomoxetine hydrochloride can be administered with or without food."/>
	<sentence id="DBMI.pac91.s16" origId="s16" text="Administration of atomoxetine hydrochloride with a standard high-fat meal in adults did not affect the extent of oral absorption of atomoxetine (AUC), but did decrease the rate of absorption, resulting in a 37% lower Cmax, and delayed Tmax by 3 hours."/>
	<sentence id="DBMI.pac91.s17" origId="s17" text="In clinical trials with children and adolescents, administration of atomoxetine hydrochloride with food resulted in a 9% lower Cmax."/>
	<sentence id="DBMI.pac91.s18" origId="s18" text="The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water."/>
	<sentence id="DBMI.pac91.s19" origId="s19" text="Volume of distribution is similar across the patient weight range after normalizing for body weight."/>
	<sentence id="DBMI.pac91.s20" origId="s20" text="At therapeutic concentrations, 98% of atomoxetine in plasma is bound to protein, primarily albumin."/>
	<sentence id="DBMI.pac91.s21" origId="s21" text="Metabolism and elimination  Atomoxetine is metabolized primarily through the CYP2D6 enzymatic pathway."/>
	<sentence id="DBMI.pac91.s22" origId="s22" text="People with reduced activity in this pathway (PMs) have higher plasma concentrations of atomoxetine compared with people with normal activity (EMs)."/>
	<sentence id="DBMI.pac91.s23" origId="s23" text="For PMs, AUC of atomoxetine is approximately 10-fold and Css,max is about 5-fold greater than EMs ."/>
	<sentence id="DBMI.pac91.s24" origId="s24" text="Laboratory tests are available to identify CYP2D6 PMs."/>
	<sentence id="DBMI.pac91.s25" origId="s25" text="Coadministration of atomoxetine hydrochloride with potent inhibitors of CYP2D6, such as fluoxetine, paroxetine, or quinidine, results in a substantial increase in atomoxetine plasma exposure, and dosing adjustment may be necessary [see Warnings and Precautions (5.13)].">
		<entity charOffset="3818-3829" id="DBMI.pac91.s25.e0" origId="s25.e0" text="fluoxetine " type="Active ingredient"/>
		<entity charOffset="3893-3905" id="DBMI.pac91.s25.e1" origId="s25.e1" text="atomoxetine " type="Active ingredient"/>
		<entity charOffset="3830-3841" id="DBMI.pac91.s25.e2" origId="s25.e2" text="paroxetine " type="Active ingredient"/>
		<entity charOffset="3845-3855" id="DBMI.pac91.s25.e3" origId="s25.e3" text="quinidine " type="Active ingredient"/>
		<pair e1="DBMI.pac91.s25.e0" e2="DBMI.pac91.s25.e1" id="DBMI.pac91.s25.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="atomoxetine " precipitant="fluoxetine "/>
		<pair e1="DBMI.pac91.s25.e0" e2="DBMI.pac91.s25.e2" id="DBMI.pac91.s25.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.s25.e0" e2="DBMI.pac91.s25.e3" id="DBMI.pac91.s25.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.s25.e1" e2="DBMI.pac91.s25.e0" id="DBMI.pac91.s25.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.s25.e1" e2="DBMI.pac91.s25.e2" id="DBMI.pac91.s25.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.s25.e1" e2="DBMI.pac91.s25.e3" id="DBMI.pac91.s25.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.s25.e2" e2="DBMI.pac91.s25.e0" id="DBMI.pac91.s25.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.s25.e2" e2="DBMI.pac91.s25.e1" id="DBMI.pac91.s25.p7" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="atomoxetine " precipitant="paroxetine "/>
		<pair e1="DBMI.pac91.s25.e2" e2="DBMI.pac91.s25.e3" id="DBMI.pac91.s25.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.s25.e3" e2="DBMI.pac91.s25.e0" id="DBMI.pac91.s25.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.s25.e3" e2="DBMI.pac91.s25.e1" id="DBMI.pac91.s25.p10" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="atomoxetine " precipitant="quinidine "/>
		<pair e1="DBMI.pac91.s25.e3" e2="DBMI.pac91.s25.e1" id="DBMI.pac91.s25.p11" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="atomoxetine " precipitant="quinidine "/>
		<pair e1="DBMI.pac91.s25.e3" e2="DBMI.pac91.s25.e2" id="DBMI.pac91.s25.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac91.s26" origId="s26" text="Atomoxetine did not inhibit or induce the CYP2D6 pathway."/>
	<sentence id="DBMI.pac91.s27" origId="s27" text="The major oxidative metabolite formed, regardless of CYP2D6 status, is 4-hydroxyatomoxetine, which is glucuronidated."/>
	<sentence id="DBMI.pac91.s28" origId="s28" text="4-Hydroxyatomoxetine is equipotent to atomoxetine as an inhibitor of the norepinephrine transporter but circulates in plasma at much lower concentrations (1% of atomoxetine concentration in EMs and 0.1% of atomoxetine concentration in PMs)."/>
	<sentence id="DBMI.pac91.s29" origId="s29" text="4-Hydroxyatomoxetine is primarily formed by CYP2D6, but in PMs, 4-hydroxyatomoxetine is formed at a slower rate by several other cytochrome P450 enzymes."/>
	<sentence id="DBMI.pac91.s30" origId="s30" text="N-Desmethylatomoxetine is formed by CYP2C19 and other cytochrome P450 enzymes, but has substantially less pharmacological activity compared with atomoxetine and circulates in plasma at lower concentrations (5% of atomoxetine concentration in EMs and 45% of atomoxetine concentration in PMs)."/>
	<sentence id="DBMI.pac91.s31" origId="s31" text="Mean apparent plasma clearance of atomoxetine after oral administration in adult EMs is 0.35 L/hr/kg and the mean half-life is 5.2 hours."/>
	<sentence id="DBMI.pac91.s32" origId="s32" text="Following oral administration of atomoxetine to PMs, mean apparent plasma clearance is 0.03 L/hr/kg and mean half-life is 21.6 hours."/>
	<sentence id="DBMI.pac91.s33" origId="s33" text="For PMs, AUC of atomoxetine is approximately 10-fold and Css,max is about 5-fold greater than EMs ."/>
	<sentence id="DBMI.pac91.s34" origId="s34" text="The elimination half-life of 4-hydroxyatomoxetine is similar to that of N-desmethylatomoxetine (6 to 8 hours) in EM subjects, while the half-life of N-desmethylatomoxetine is much longer in PM subjects (34 to 40 hours)."/>
	<sentence id="DBMI.pac91.s35" origId="s35" text="Atomoxetine is excreted primarily as 4-hydroxyatomoxetine-O-glucuronide, mainly in the urine (greater than 80% of the dose) and to a lesser extent in the feces (less than 17% of the dose)."/>
	<sentence id="DBMI.pac91.s36" origId="s36" text="Only a small fraction of the atomoxetine hydrochloride dose is excreted as unchanged atomoxetine (less than 3% of the dose), indicating extensive biotransformation."/>
	<sentence id="DBMI.pac91.s37" origId="s37" text="[See Use In Specific Populations (8.4, 8.5, 8.6, 8.7, 8.8, 8.9)]."/>
	<sentencespan id="DBMI.pac91.sp0" origId="sp0" text="12 CLINICAL PHARMACOLOGY\n\n12.1 Mechanism of Action\n\nThe precise mechanism by which atomoxetine produces its therapeutic effects in Attention-Deficit/Hyperactivity Disorder (ADHD) is unknown, but is thought to be related to selective inhibition of the pre-synaptic norepinephrine transporter, as determined in ex vivo uptake and neurotransmitter depletion studies. 12.2 Pharmacodynamics\n\nAn exposure-response analysis encompassing doses of atomoxetine (0.5, 1.2 or 1.8 mg/kg/day) or placebo demonstrated atomoxetine exposure correlates with efficacy as measured by the Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator administered and scored. The exposure-efficacy relationship was similar to that observed between dose and efficacy with median exposures at the two highest doses resulting in near maximal changes from baseline [see Clinical Studies  (14.2)]."/>
	<sentencespan id="DBMI.pac91.sp1" origId="sp1" text="12.3 Pharmacokinetics\n\nAtomoxetine is well-absorbed after oral administration and is minimally affected by food. It is eliminated primarily by oxidative metabolism through the cytochrome P450 2D6 (CYP2D6) enzymatic pathway and subsequent glucuronidation. Atomoxetine has a half-life of about 5 hours."/>
	<sentencespan id="DBMI.pac91.sp2" origId="sp2" text="A fraction of the population (about 7% of Caucasians and 2% of African Americans) are poor metabolizers (PMs) of CYP2D6 metabolized drugs. These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (EMs)]. Drugs that inhibit CYP2D6, such as fluoxetine, paroxetine, and quinidine, cause similar increases in exposure.">
		<entity charOffset="1654-1665" id="DBMI.pac91.sp2.e0" origId="sp2.e0" text="fluoxetine " type="Active ingredient"/>
		<entity charOffset="1533-1545" id="DBMI.pac91.sp2.e1" origId="sp2.e1" text="atomoxetine " type="Active ingredient"/>
		<entity charOffset="1666-1677" id="DBMI.pac91.sp2.e2" origId="sp2.e2" text="paroxetine " type="Active ingredient"/>
		<entity charOffset="1682-1692" id="DBMI.pac91.sp2.e3" origId="sp2.e3" text="quinidine " type="Active ingredient"/>
		<pair e1="DBMI.pac91.sp2.e0" e2="DBMI.pac91.sp2.e1" id="DBMI.pac91.sp2.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="atomoxetine " precipitant="fluoxetine "/>
		<pair e1="DBMI.pac91.sp2.e0" e2="DBMI.pac91.sp2.e2" id="DBMI.pac91.sp2.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.sp2.e0" e2="DBMI.pac91.sp2.e3" id="DBMI.pac91.sp2.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.sp2.e1" e2="DBMI.pac91.sp2.e0" id="DBMI.pac91.sp2.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.sp2.e1" e2="DBMI.pac91.sp2.e2" id="DBMI.pac91.sp2.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.sp2.e1" e2="DBMI.pac91.sp2.e3" id="DBMI.pac91.sp2.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.sp2.e2" e2="DBMI.pac91.sp2.e0" id="DBMI.pac91.sp2.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.sp2.e2" e2="DBMI.pac91.sp2.e1" id="DBMI.pac91.sp2.p7" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="atomoxetine " precipitant="paroxetine "/>
		<pair e1="DBMI.pac91.sp2.e2" e2="DBMI.pac91.sp2.e3" id="DBMI.pac91.sp2.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.sp2.e3" e2="DBMI.pac91.sp2.e0" id="DBMI.pac91.sp2.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.sp2.e3" e2="DBMI.pac91.sp2.e1" id="DBMI.pac91.sp2.p10" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="atomoxetine " precipitant="quinidine "/>
		<pair e1="DBMI.pac91.sp2.e3" e2="DBMI.pac91.sp2.e2" id="DBMI.pac91.sp2.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac91.sp3" origId="sp3" text="The pharmacokinetics of atomoxetine have been evaluated in more than 400 children and adolescents in selected clinical trials, primarily using population pharmacokinetic studies. Single-dose and steady-state individual pharmacokinetic data were also obtained in children, adolescents, and adults. When doses were normalized to a mg/kg basis, similar half-life, Cmax, and AUC values were observed in children, adolescents, and adults."/>
	<sentencespan id="DBMI.pac91.sp4" origId="sp4" text="Clearance and volume of distribution after adjustment for body weight were also similar. Absorption and distribution Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in EMs and 94% in PMs. Maximal plasma concentrations (Cmax) are reached approximately 1 to 2 hours after dosing."/>
	<sentencespan id="DBMI.pac91.sp5" origId="sp5" text="Atomoxetine hydrochloride can be administered with or without food. Administration of atomoxetine hydrochloride with a standard high-fat meal in adults did not affect the extent of oral absorption of atomoxetine (AUC), but did decrease the rate of absorption, resulting in a 37% lower Cmax, and delayed Tmax by 3 hours. In clinical trials with children and adolescents, administration of atomoxetine hydrochloride with food resulted in a 9% lower Cmax."/>
	<sentencespan id="DBMI.pac91.sp6" origId="sp6" text="The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water. Volume of distribution is similar across the patient weight range after normalizing for body weight. At therapeutic concentrations, 98% of atomoxetine in plasma is bound to protein, primarily albumin."/>
	<sentencespan id="DBMI.pac91.sp7" origId="sp7" text="Metabolism and elimination  Atomoxetine is metabolized primarily through the CYP2D6 enzymatic pathway. People with reduced activity in this pathway (PMs) have higher plasma concentrations of atomoxetine compared with people with normal activity (EMs). For PMs, AUC of atomoxetine is approximately 10-fold and Css,max is about 5-fold greater than EMs ."/>
	<sentencespan id="DBMI.pac91.sp8" origId="sp8" text="Laboratory tests are available to identify CYP2D6 PMs. Coadministration of atomoxetine hydrochloride with potent inhibitors of CYP2D6, such as fluoxetine, paroxetine, or quinidine, results in a substantial increase in atomoxetine plasma exposure, and dosing adjustment may be necessary [see Warnings and Precautions (5.13)]. Atomoxetine did not inhibit or induce the CYP2D6 pathway.">
		<entity charOffset="3818-3829" id="DBMI.pac91.sp8.e0" origId="sp8.e0" text="fluoxetine " type="Active ingredient"/>
		<entity charOffset="3893-3905" id="DBMI.pac91.sp8.e1" origId="sp8.e1" text="atomoxetine " type="Active ingredient"/>
		<entity charOffset="3830-3841" id="DBMI.pac91.sp8.e2" origId="sp8.e2" text="paroxetine " type="Active ingredient"/>
		<entity charOffset="3845-3855" id="DBMI.pac91.sp8.e3" origId="sp8.e3" text="quinidine " type="Active ingredient"/>
		<pair e1="DBMI.pac91.sp8.e0" e2="DBMI.pac91.sp8.e1" id="DBMI.pac91.sp8.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="atomoxetine " precipitant="fluoxetine "/>
		<pair e1="DBMI.pac91.sp8.e0" e2="DBMI.pac91.sp8.e2" id="DBMI.pac91.sp8.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.sp8.e0" e2="DBMI.pac91.sp8.e3" id="DBMI.pac91.sp8.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.sp8.e1" e2="DBMI.pac91.sp8.e0" id="DBMI.pac91.sp8.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.sp8.e1" e2="DBMI.pac91.sp8.e2" id="DBMI.pac91.sp8.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.sp8.e1" e2="DBMI.pac91.sp8.e3" id="DBMI.pac91.sp8.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.sp8.e2" e2="DBMI.pac91.sp8.e0" id="DBMI.pac91.sp8.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.sp8.e2" e2="DBMI.pac91.sp8.e1" id="DBMI.pac91.sp8.p7" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="atomoxetine " precipitant="paroxetine "/>
		<pair e1="DBMI.pac91.sp8.e2" e2="DBMI.pac91.sp8.e3" id="DBMI.pac91.sp8.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.sp8.e3" e2="DBMI.pac91.sp8.e0" id="DBMI.pac91.sp8.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac91.sp8.e3" e2="DBMI.pac91.sp8.e1" id="DBMI.pac91.sp8.p10" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="atomoxetine " precipitant="quinidine "/>
		<pair e1="DBMI.pac91.sp8.e3" e2="DBMI.pac91.sp8.e1" id="DBMI.pac91.sp8.p11" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="atomoxetine " precipitant="quinidine "/>
		<pair e1="DBMI.pac91.sp8.e3" e2="DBMI.pac91.sp8.e2" id="DBMI.pac91.sp8.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac91.sp9" origId="sp9" text="The major oxidative metabolite formed, regardless of CYP2D6 status, is 4-hydroxyatomoxetine, which is glucuronidated. 4-Hydroxyatomoxetine is equipotent to atomoxetine as an inhibitor of the norepinephrine transporter but circulates in plasma at much lower concentrations (1% of atomoxetine concentration in EMs and 0.1% of atomoxetine concentration in PMs). 4-Hydroxyatomoxetine is primarily formed by CYP2D6, but in PMs, 4-hydroxyatomoxetine is formed at a slower rate by several other cytochrome P450 enzymes."/>
	<sentencespan id="DBMI.pac91.sp10" origId="sp10" text="N-Desmethylatomoxetine is formed by CYP2C19 and other cytochrome P450 enzymes, but has substantially less pharmacological activity compared with atomoxetine and circulates in plasma at lower concentrations (5% of atomoxetine concentration in EMs and 45% of atomoxetine concentration in PMs). Mean apparent plasma clearance of atomoxetine after oral administration in adult EMs is 0.35 L/hr/kg and the mean half-life is 5.2 hours. Following oral administration of atomoxetine to PMs, mean apparent plasma clearance is 0.03 L/hr/kg and mean half-life is 21.6 hours."/>
	<sentencespan id="DBMI.pac91.sp11" origId="sp11" text="For PMs, AUC of atomoxetine is approximately 10-fold and Css,max is about 5-fold greater than EMs . The elimination half-life of 4-hydroxyatomoxetine is similar to that of N-desmethylatomoxetine (6 to 8 hours) in EM subjects, while the half-life of N-desmethylatomoxetine is much longer in PM subjects (34 to 40 hours). Atomoxetine is excreted primarily as 4-hydroxyatomoxetine-O-glucuronide, mainly in the urine (greater than 80% of the dose) and to a lesser extent in the feces (less than 17% of the dose)."/>
	<sentencespan id="DBMI.pac91.sp12" origId="sp12" text="Only a small fraction of the atomoxetine hydrochloride dose is excreted as unchanged atomoxetine (less than 3% of the dose), indicating extensive biotransformation. [See Use In Specific Populations (8.4, 8.5, 8.6, 8.7, 8.8, 8.9)]."/>
</document>
